Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

45.30 +2.70 (+6.34%)
Streaming Delayed Price Updated: 12:08 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year... 
Via StockStory
Bristol Myers Squibb Co (NYSE:BMY) Q3 2025 Earnings Beat Estimates
Bristol Myers Squibb Q3 2025 earnings beat estimates with $1.63 EPS and $12.22B revenue, driven by strong new product sales. 
Via Chartmill
Topics Earnings
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
What to Expect from Bristol-Myers Squibb's Earnings
 
Via Benzinga
Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal
Via Stocktwits
Price Over Earnings Overview: Bristol-Myers Squibb
 
Via Benzinga
Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
From Bristol Myers Squibb
Via Business Wire
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
From Bristol Myers Squibb
Via Business Wire
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through. 
Via The Motley Fool
Topics Workforce
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Why Replimune Stock Was Soaring Today
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks. 
Via The Motley Fool
2 High-Yield Dividend Stocks Too Cheap to Ignore
They are both yielding above 5%. 
Via The Motley Fool
Topics Intellectual Property World Trade
3 S&P 500 Stocks We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?
All of the top 20 drugmakers have a subscription with this software business. 
Via The Motley Fool
Topics Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
From Bristol Myers Squibb
Via Business Wire
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portfolio. 
Via Benzinga
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
From Bristol Myers Squibb
Via Business Wire
3 Value Stocks with Warning Signs
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a High Dividend Yield and Strong Profitability
Bristol Myers Squibb (BMY) offers a high 5.42% dividend yield with strong profitability and a decade of consistent payouts, making it a top stock for income investors. 
Via Chartmill
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Presents a Strong Value Investment Case
Bristol-Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a solid 5.4% dividend yield, presenting a compelling case for value investors. 
Via Chartmill
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.